BRCA1 and breast carcinoma: Indeed, in a phase 2 randomized trial of BRCA1/2 mutated, locally advanced or metastatic non-HER2-positive breast cancer (NCT02849496), 78 patients are divided into two cohorts, one treated with Olaparib, and the other treated with Olaparib plus atezolizumab.